Jeffrey Drazen, MD – Editor-in-Chief of The New England Journal of Medicine –

Clinical trial data are high-quality data that have been obtained because patients put themselves at risk to participate in the trial and clinical trialists designed and implemented a clinical trial to answer a specific question. In this talk, we will explore by example how clinical trial data have or have not been shared and the consequences thereof. We will show how the use of medical illustration can provide clarity and emphasis in demonstrating how clinical trial data can be manipulated and ways to mitigate this problem. We will then explore the imperatives for and barriers to clinical trial data sharing ending with the recommendations of the International Committee of Medical Journal Editors to share these data. We will show how illustrators can take an idea that is difficult to grasp and provide visual context that leads to clarity of explication.

Speaker Bio

Born in Clayton, Missouri, Dr. Drazen graduated from Tufts University and Harvard Medical School. He served his medical internship and residency at Boston’s Peter Bent Brigham Hospital and was a clinical fellow and research fellow at Harvard Medical School and Harvard School of Public Health. Thereafter, he joined the Pulmonary Divisions of the Brigham and Women’s and Beth Israel Hospitals, serving as chief of their Pulmonary Divisions for many years.

His current appointments include senior physician at Brigham and Women’s Hospital, Distinguished Parker B. Francis Professor of Medicine at Harvard Medical School, professor of physiology at the Harvard School of Public Health and adjunct professor of medicine at the Boston University School of Medicine.

In 2000, he became editor-in-chief of the New England Journal of Medicine. Since then, the Journal has published major papers advancing the science of medicine, including the first descriptions of SARS, timely coverage of the Ebola and Zika virus epidemics, and major advances in the treatment of cancer, heart disease and lung disease. It has been at the forefront of worldwide efforts to register all clinical trials and to share clinical trial data.  The Journal has more than half a million readers every week and the highest impact factor of any medical journal publishing original research.